Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...

Posay, the dermatologist-recommended leader in skincare, is thrilled to announce its partnership with the BNP Paribas Open as ...

Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...

Genentech, a member of the Roche Group, announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health-sponsored Phase III OUtMATCH study, which provide ...

The value that laboratories contribute to clinical decision-making is critical to the future of health care and enables ...